182 related articles for article (PubMed ID: 35988810)
21. NITROSOGENESIS OF SKIN (HUMAN) CANCER- THE HIDDEN TRUTH OF A NEVERENDING STORY: NITROSAMINE CONTAMINATION IN OLMESARTAN, VALSARTAN AND HCT AS MAIN RISK FACTOR FOR THE DEVELOPMENT OF KERATINOCYTE CANCER.
Tchernev G; Kordeva S
Georgian Med News; 2023 Apr; (337):63-67. PubMed ID: 37354675
[TBL] [Abstract][Full Text] [Related]
22. Use of the bacterial reverse mutation assay to predict carcinogenicity of N-nitrosamines.
Trejo-Martin A; Bercu JP; Thresher A; Tennant RE; Thomas RF; Cross K; Czich A; Waese K; Nicolette JJ; Murray J; Sonders P; Kondratiuk A; Cheung JR; Thomas D; Lynch A; Harvey J; Glowienke S; Custer L; Escobar PA
Regul Toxicol Pharmacol; 2022 Nov; 135():105247. PubMed ID: 35998738
[TBL] [Abstract][Full Text] [Related]
23. Practical and Science-Based Strategy for Establishing Acceptable Intakes for Drug Product
Dobo KL; Kenyon MO; Dirat O; Engel M; Fleetwood A; Martin M; Mattano S; Musso A; McWilliams JC; Papanikolaou A; Parris P; Whritenour J; Yu S; Kalgutkar AS
Chem Res Toxicol; 2022 Mar; 35(3):475-489. PubMed ID: 35212515
[TBL] [Abstract][Full Text] [Related]
24. Simultaneous Estimation of Six Nitrosamine Impurities in Valsartan Using Liquid Chromatographic Method.
Bodiwala KB; Panchal BG; Savale SS; Dave JB; Sureja DK; Dhameliya TM; Chhabria MT
J AOAC Int; 2022 Feb; 105(1):1-10. PubMed ID: 34338773
[TBL] [Abstract][Full Text] [Related]
25. Simultaneous detection of nitrosamines and other sartan-related impurities in active pharmaceutical ingredients by supercritical fluid chromatography.
Schmidtsdorff S; Schmidt AH
J Pharm Biomed Anal; 2019 Sep; 174():151-160. PubMed ID: 31174128
[TBL] [Abstract][Full Text] [Related]
26. The EU Response to the Presence of Nitrosamine Impurities in Medicines.
Ruepp R; Frötschl R; Bream R; Filancia M; Girard T; Spinei A; Weise M; Whomsley R
Front Med (Lausanne); 2021; 8():782536. PubMed ID: 34869504
[TBL] [Abstract][Full Text] [Related]
27. N-Nitrosamine Formation in Pharmaceutical Solid Drug Products: Experimental Observations.
Moser J; Ashworth IW; Harris L; Hillier MC; Nanda KK; Scrivens G
J Pharm Sci; 2023 May; 112(5):1255-1267. PubMed ID: 36736774
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of Nitrosamine Mutagenicity and Their Relationship to Rodent Carcinogenic Potency.
Snodin DJ; Trejo-Martin A; Ponting DJ; Smith GF; Czich A; Cross K; Custer L; Elloway J; Greene N; Kalgutkar AS; Stalford SA; Tennant RE; Vock E; Zalewski A; Ziegler V; Dobo KL
Chem Res Toxicol; 2024 Feb; 37(2):181-198. PubMed ID: 38316048
[TBL] [Abstract][Full Text] [Related]
29. A Nitrite Excipient Database: A Useful Tool to Support N-Nitrosamine Risk Assessments for Drug Products.
Boetzel R; Schlingemann J; Hickert S; Korn C; Kocks G; Luck B; Blom G; Harrison M; François M; Allain L; Wu Y; Bousraf Y
J Pharm Sci; 2023 Jun; 112(6):1615-1624. PubMed ID: 35500671
[TBL] [Abstract][Full Text] [Related]
30. Short commentary on NDMA (N-nitrosodimethylamine) contamination of valsartan products.
Snodin DJ; Elder DP
Regul Toxicol Pharmacol; 2019 Apr; 103():325-329. PubMed ID: 30629969
[TBL] [Abstract][Full Text] [Related]
31. High mutagenic activity of N-nitrosobis(2-oxopropyl)amine and N-nitrosobis(2-hydroxypropyl)amine in the host-mediated assay in hamsters: evidence for premutagenic methyl and hydroxylpropyl adducts.
Guttenplan JB; Kokkinakis D
Carcinogenesis; 1993 Aug; 14(8):1621-5. PubMed ID: 8353845
[TBL] [Abstract][Full Text] [Related]
32. Nitrosamine acceptable intakes should consider variation in molecular weight: The implication of stoichiometric DNA damage.
Fine J; Allain L; Schlingemann J; Ponting DJ; Thomas R; Johnson GE
Regul Toxicol Pharmacol; 2023 Dec; 145():105505. PubMed ID: 37805106
[TBL] [Abstract][Full Text] [Related]
33. The contamination of valsartan and other sartans, Part 2: Untargeted screening reveals contamination with amides additionally to known nitrosamine impurities.
Scherf-Clavel O; Kinzig M; Besa A; Schreiber A; Bidmon C; Abdel-Tawab M; Wohlfart J; Sörgel F; Holzgrabe U
J Pharm Biomed Anal; 2019 Aug; 172():278-284. PubMed ID: 31078064
[TBL] [Abstract][Full Text] [Related]
34. Volatile nitrosamine levels and genotoxicity of food samples from high-risk areas for nasopharyngeal carcinoma before and after nitrosation.
Poirier S; Bouvier G; Malaveille C; Ohshima H; Shao YM; Hubert A; Zeng Y; de Thé G; Bartsch H
Int J Cancer; 1989 Dec; 44(6):1088-94. PubMed ID: 2558079
[TBL] [Abstract][Full Text] [Related]
35. Nitrosamines crisis in pharmaceuticals - Insights on toxicological implications, root causes and risk assessment: A systematic review.
Vikram HPR; Kumar TP; Kumar G; Beeraka NM; Deka R; Suhail SM; Jat S; Bannimath N; Padmanabhan G; Chandan RS; Kumar P; Gurupadayya B
J Pharm Anal; 2024 May; 14(5):100919. PubMed ID: 38799236
[TBL] [Abstract][Full Text] [Related]
36. Current status and prospects of development of analytical methods for determining nitrosamine and N-nitroso impurities in pharmaceuticals.
Wichitnithad W; Nantaphol S; Noppakhunsomboon K; Thitikornpong W; Rojsitthisak P
Talanta; 2023 Mar; 254():124102. PubMed ID: 36470020
[TBL] [Abstract][Full Text] [Related]
37. Can in vitro mammalian cell genotoxicity test results be used to complement positive results in the Ames test and help predict carcinogenic or in vivo genotoxic activity? I. Reports of individual databases presented at an EURL ECVAM Workshop.
Kirkland D; Zeiger E; Madia F; Gooderham N; Kasper P; Lynch A; Morita T; Ouedraogo G; Parra Morte JM; Pfuhler S; Rogiers V; Schulz M; Thybaud V; van Benthem J; Vanparys P; Worth A; Corvi R
Mutat Res Genet Toxicol Environ Mutagen; 2014 Dec; 775-776():55-68. PubMed ID: 25435356
[TBL] [Abstract][Full Text] [Related]
38. Development of GC-MS/MS Method for Simultaneous Estimation of Four Nitrosoamine Genotoxic Impurities in Valsartan.
Tummala SR; Amgoth KP
Turk J Pharm Sci; 2022 Aug; 19(4):455-461. PubMed ID: 36047600
[TBL] [Abstract][Full Text] [Related]
39. GFP-fused yeast cells as whole-cell biosensors for genotoxicity evaluation of nitrosamines.
He Y; Ding H; Xia X; Qi W; Wang H; Liu W; Zheng F
Appl Microbiol Biotechnol; 2021 Jul; 105(13):5607-5616. PubMed ID: 34228183
[TBL] [Abstract][Full Text] [Related]
40. Nitrosated Active Pharmaceutical Ingredients - Lessons Learned?
Holzgrabe U
J Pharm Sci; 2023 May; 112(5):1210-1215. PubMed ID: 36720391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
